Biofrontera Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc (BFRI) reports a 17% revenue increase and significant margin expansion, while navigating increased expenses and regulatory uncertainties.
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call May 14, 2026 11:00 AM EDTCompany ParticipantsHermann Lubbert - CEO, President & ChairmanGeorge Jones -...
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -127.78% and +6.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Biofrontera Inc (BFRI) reports a profitable Q4 with significant revenue growth and strategic transactions enhancing future prospects.
Need a quote from a Motley Fool analyst? The risks and uncertainties associated with the company's business are detailed in and are qualified by the cautionary statements contained in Biofrontera Inc.'s press releases and SEC filings, including the company's Annual Report on Form 10-K for the year ended 12/31/2025.
Biofrontera Inc. (BFRI) Q4 2025 Earnings Call March 19, 2026 10:00 AM EDTCompany ParticipantsHermann Lubbert - CEO, President & ChairmanGeorge Jones -...
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met with high statistical significance (p <0.0001)Favorable recurrence outcomes at one-year follow-upBCC is the most common skin cancer in the US with more than 3 million cases diagnosed annually1 WOBURN, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call November 13, 2025 10:00 AM ESTCompany ParticipantsHermann Lubbert - CEO, President & ChairmanEugene...
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability.Proceeds will support the growth of Biofrontera’s commercial photodynamic therapy (PDT) platform, and expansion of Ameluz® into additional indications. WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting childrenImpetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric officesPrivate convertible notes financing will supp
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results,
Biofrontera Inc. (BFRI) announced the closing of its restructuring and asset purchase agreement with its former parent company, Biofrontera AG. Under the transaction, Biofrontera Inc. has acquired all U.S. assets and rights related to Ameluz and RhodoLED, including the New Drug Application, Investigational New Drug Application, manufacturing rights and contracts, all intellectual property, and related personnel. As a result of the transaction, Biofrontera Inc. will now pay a monthly earnout of 1
Biofrontera Inc. (BFRI) announced the closing of its restructuring and asset purchase agreement with its former parent company, Biofrontera AG. Under the transaction, Biofrontera Inc. has acquired all U.S. assets and rights related to Ameluz and RhodoLED, including the New Drug Application, Investigational New Drug Application, manufacturing rights and contracts, all intellectual property, and related personnel. As a result of the transaction, Biofrontera Inc. will now pay a monthly earnout of 1
Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%.Closing releases final $2.5 million of $11 million financing led by existing investors Rosalind Advisors and AIGH Capital Management, which is expected to fund Biofrontera Inc. to profitability. WOBURN, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera I
We feel now is a pretty good time to analyse Biofrontera Inc.'s ( NASDAQ:BFRI ) business as it appears the company may...
We feel now is a pretty good time to analyse Biofrontera Inc.'s ( NASDAQ:BFRI ) business as it appears the company may...
Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 1:15 p.m. ET
WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has engaged Lytham Partners to lead a strategic investor relations and shareholder communication program. For more than 20 years, Lytham Partners has been one of the country's leading investor relations firms, having created one of the industry's largest and most diverse
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026 WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercial
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of phot